Nafees Uddin Chowdhury, Tasdik Farooq, Shahanshah Abdullah, Ahmed Shohrawar Mahadi, Md Mehedee Hasan, Tasfiq Zaman Paran, Nahid Hasan, Md Mohabbulla Mohib, Md Abu Taher Sagor, Md Ashraful Alam
Matrix metalloproteinase (MMPs) family members are well known signaling molecules. MMPs are involved in tissue remodeling and are affiliated with several pathological, pharmacological and physiological processes. In addition, these also facilitate other downstream pathways such as cellular inflammation. However, members of this family are being investigated in several diseases as a clinical marker. These proteins are often found responsible in the development of various dysfunctions such as cardiovascular, kidney, liver, and nervous system disorder. Evidences also suggest that MMPs take part in organ rejections during organ transplantations. Besides, MMPs also trigger accumulation of unnecessary immune cells which further exacerbate the situation resulting in a drug therapy failure. Furthermore, many harmful downstream kinases are induced by MMPs signaling. Therefore, it has been an imperative issue to establish a noble and alternative drug therapy against MMPs family for ensuring safety against several lives threatening phenomenon. Thus this review will explain the molecular mechanism of MMP family members and few possible drug therapies modulating MMPs function.
